Press Releases

European Commission Grants Orphan Medicinal Product Designation for Emmaus Medical’s Sickle Cell TreatmentJuly 17, 2012

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission (EC) has granted Orphan Medicinal Product designation for the company’s investigational drug Levoglutamide (L-glutamine) for the treatment of sickle cell disease.

Emmaus Medical’s Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Status from European Medicines Agency May 29, 2012

Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).

Dr. Henry A. McKinnell Jr., Former Pfizer CEO, Joins Emmaus Medical, Inc. Board of DirectorsMay 18, 2010

Sickle Cell Treatment Approved for Phase III Clinical TrialApril 24, 2009

EMD Serono, Inc.January 12, 2009